Another larger scaled phase II clinical trial of Ervogastat with NASH is ongoing, aiming to assess the efficacy and safety of the inhibition of DGAT2 and ACC to resolve NASH with fibrosis (NCT04321031) [165]. This evidence concerns the gene DGAT2 and metabolic dysfunction-associated steatohepatitis.